## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.7% below STRENGTH zone (4.0-10.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($213.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Jump Financial LLC Decreases Position in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T114710 | Neutral | Relevance: 99%
-  Jump Financial LLC significantly reduced its stake in Danaher Corporation by 34.2% in the second quarter, now holding 79,091 shares valued at $15.62 million. Meanwhile, other institutional investors like Norges Bank and Nuveen LLC acquired substantial new positions in Danaher, and insiders sold shares worth over $6.6 million in the last three months. Analyst ratings for Danaher are predominantly "Buy" with an average price target of $245.75, and the company recently announced a quarterly dividend of $0.32 per share.

**2. Danaher Corporation $DHR Holdings Raised by Thematics Asset Management**
- Source: MarketBeat | 20251208T121605 | Bullish | Relevance: 98%
-  Thematics Asset Management significantly increased its stake in Danaher Corporation (NYSE: DHR) by 12.5% in Q2, bringing their total holdings to 84,702 shares valued at $16.73 million. This comes despite recent insider selling by executives. Danaher reported strong Q3 earnings, beating analyst estimates with an EPS of $1.89 and revenue of $6.05 billion, and maintains a "Moderate Buy" consensus rating among analysts.

**3. A year of science in motion**
- Source: Danaher Corporation | 20251209T160805 | Bullish | Relevance: 98%
-  The year 2025 saw significant advancements across life science, diagnostics, and bioprocessing, particularly in personalized medicine and CAR-T therapies. A key highlight was the administration of the world's first personalized CRISPR therapy to a baby with a rare genetic disorder, accelerated by Danaher companies. Additionally, Danaher company Cytiva is leading a collaborative effort to develop a more cost-effective in vivo CAR-T cell therapy platform, and breakthroughs in Alzheimer's diagnostics are improving early detection.

**4. Vega Investment Solutions Has $1.37 Million Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T132406 | Somewhat-Bullish | Relevance: 98%
- Vega Investment Solutions significantly reduced its stake in Danaher Corporation (NYSE:DHR) by 76.7% in Q2, selling 22,814 shares and retaining 6,942 shares valued at approximately $1.37 million. Danaher exceeded Q3 earnings expectations with an EPS of $1.89 and revenue of $6.05 billion, while analysts have a "Moderate Buy" rating for the stock with an average price target of $245.75. Insiders have sold a significant number of shares recently, though institutional investors hold a substantial stake in the company.

**5. Rivulet Capital LLC Has $114.33 Million Stock Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T123905 | Somewhat-Bullish | Relevance: 98%
-  Rivulet Capital LLC increased its stake in Danaher Corporation by 10.1% during the second quarter, bringing its total holdings to 578,750 shares valued at $114.33 million. This makes Danaher the firm's second-largest holding, representing 11.1% of its investment portfolio. Other institutional investors like Vanguard Group Inc. and Price T Rowe Associates Inc. MD also significantly modified their holdings in Danaher.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $76M sold (10 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.5x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $159.8B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.5 |
| Current P/E | 28.9 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.1% to -2.7% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.7pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.75), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.69% (CS: 38) | Weak |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $223.23
- **Stop Loss:** $213.79 (4.2% risk)
- **Target:** $232.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $6,920.13
- **Portfolio %:** 6.92%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*